Diabetes, Vol 40, Issue 11 1430-1434, Copyright © 1991 by American Diabetes Association

ARTICLES

Anti-CD8 abrogates effect of anti-CD4-mediated islet allograft survival in rat model

K Seydel, J Shizuru, D Grossman, A Wu, S Alters and CG Fathman
Department of Medicine, Stanford University School of Medicine, California 94305-5111.

We studied the effects of anti-CD4 treatment of diabetic ACI rats on the induction of tolerance to allogeneic (Lewis) islet allografts. When given as a 4-day treatment regimen, OX38, a mouse anti-rat CD4 antibody, caused depletion of greater than 80% of CD4+ cells from the peripheral blood of treated rats. After induction of diabetes (a single high-dose bolus of streptozocin) and 3 days after the initiation of anti-CD4 immunotherapy, recipient ACI rats were transplanted with fully allogeneic (Lewis) islets of Langerhans via the portal circulation. These transplanted islets were capable of returning the anti-CD4-treated ACI recipients to normoglycemia, which was maintained indefinitely in the absence of further immunosuppression. In contrast, treatment of recipient rats with OX8, an anti-CD8 monoclonal antibody (MoAb), induced only a slight prolongation of graft survival (less than or equal to 30 days). Further characterization of the cellular requirements for the induction of long-term transplantation survival revealed that successful pretransplantation anti-CD4 therapy could be ablated by the coincident treatment of recipient rats with depleting levels of anti-CD8 MoAb. These data point to the necessity of a regulator CD8+ cell in the induction of anti-CD4-mediated transplantation survival in this rat model of islet transplantation.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. A. ROSSINI, D. L. GREINER, and J. P. MORDES Induction of Immunologic Tolerance for Transplantation Physiol Rev, January 1, 1999; 79(1): 99 - 141. [Abstract] [Full Text] [PDF]